Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
July 13, 2009

Sirius and Assistance Publique-Hopitaux de Paris to Research Genomics in Sepsis Patients

  • Sirius Genomics signed an agreement with the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic correlations in severe sepsis patients. This work will help Sirius develop a test to assess responsiveness to recombinant human activated protein C, which is sold by Eli Lilly under the trademark Xigris ®, in patients with severe sepsis at high risk of death.

    “Access to AP-HP's severe sepsis patients will be critical in the validation of Sirius' sepsis biomarkers,” notes Brad Popovich, Ph.D., president and CEO of Sirius.

    In May Sirius entered a deal with Vanderbilt University that would also aid in the development of the Xigris companion diagnostic. The arrangement allows the firm to study patients enrolled in Vanderbilt’s Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study.

     

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.